ABVX · Abivax SA

The thesis

Abivax is a one-drug company, and the case still rests on a US marketing application (new drug application, NDA) for obefazimod in ulcerative colitis that the company guides to the fourth quarter of 2026. The shares closed at $87.00 on 27 October 2026, 40.1% below the 52-week high of $145.31, so the price carries more doubt than the filing guidance implies. The NDA submission, due by 31 December 2026, settles whether that doubt is warranted.

The UEG Week congress (United European Gastroenterology, 17 October to 20 October 2026) has passed. Searches of company releases and press coverage found no announcement of new efficacy or safety findings from it, and no change to the filing timetable since the half-year results of 21 September 2026. Those results reported a first-half net loss of €165.9 million and cash and short-term investments of €402.4 million at 30 June 2026; with €767.1 million of net proceeds from the July offering, the company guides funding into the fourth quarter of 2029.

The narrative is maturing: coverage is broad, and the shares have stayed near $87 since the $87.98 close of 14 October 2026, after $95.10 on 1 October 2026. The 14-day relative strength index (RSI, a 0-100 gauge of recent buying versus selling) read 50.0 on 27 October 2026, up from 38.7 on 14 October 2026. Wedbush cut its target again on 21 October 2026, while Guggenheim kept its Buy rating and $175 target on 20 October 2026.

Bullish and bearish views on Abivax SA

The bull case on Abivax SA (ABVX), in brief: The filing timetable is intact. The bear case: Analysts keep trimming targets.

Bull case

• The filing timetable is intact. Abivax said at its 21 September 2026 half-year results that it remains on track to submit the NDA in the fourth quarter of 2026, after a positive pre-NDA meeting with the US Food and Drug Administration (FDA) on content, format and strategy.
• Maintenance efficacy is documented. The company's 1 June 2026 release reported Week-44 clinical remission of 50.8% at 25 mg and 51.3% at 50 mg, against 10.4% on placebo.
• Funding runs well past launch. Cash of €402.4 million at 30 June 2026 plus €767.1 million of net July proceeds supports operations into the fourth quarter of 2029, per the half-year release.
• Most analysts still rate it positively. Guggenheim reiterated Buy with a $175 target on 20 October 2026, and BTIG held $175 on 22 September 2026. MarketBeat showed a consensus target of $156.69 on 28 September 2026.
• Takeover interest has been reported. La Lettre reported on 17 July 2026, as relayed by Benzinga, that Abivax re-engaged the investment bank Centerview for talks with large drugmakers. The company has not confirmed any approach.

Bear case

• Analysts keep trimming targets. Wedbush lowered its target to $96 with a Neutral rating on 21 October 2026, after cutting from $140 to $118 on 22 September 2026. Truist cut from $155 to $151 on the same earlier date.
• The price sits far below the offering. The July offering priced 6.40 million American depositary shares (ADSs) at $125.00 each (Benzinga, 1 July 2026), and the close of $87.00 on 27 October 2026 is 30.4% under that price.
• Losses are widening. The first-half 2026 net loss was €165.9 million, against €100.8 million a year earlier, per the half-year results.
• One asset carries the company. A safety question, including the malignancy cases the company has reported in the 50 mg group, or an FDA request for more data would hit the whole valuation. No such request has been disclosed.
• Options attention is heavy. Benzinga listed Abivax among large options-activity alerts for health care stocks on 1 July 2026, 9 July 2026, 21 July 2026 and 23 October 2026, a sign of speculative positioning around a binary event.

Price setup

The adjusted daily close was $87.00 on 27 October 2026. That is 40.1% below the 52-week high of $145.31 and 30.0% lower than three months earlier. The shares closed at $95.10 on 1 October 2026 and $87.98 on 14 October 2026, so the past two weeks were flat after a sharp decline.

The $85 level in the previous note sits 2.3% below the latest close. A close under it would extend the post-results decline. The 50-day and 200-day moving averages stood near $117 on 28 September 2026 per MarketBeat, so the shares trade well under both.

Crowding evidence is mixed. As a foreign issuer, Abivax files no SEC Form 4 insider-transaction reports, so insider selling cannot be observed there.

Catalysts, next 30 days

• Any date: An Abivax announcement of NDA submission or a change to its timing. The company guides to the fourth quarter; the estimated deadline of ~31 December 2026 falls outside the 30-day window but decides the case.
• Any date: Further analyst target changes. Wedbush, Truist and Guggenheim have each moved or restated targets in the last six weeks.

What would change the view

The case breaks if Abivax moves the NDA submission into 2027 or discloses an FDA request for added safety work. Either would end the argument that the filing is a near-term milestone.

A daily close below $85 would extend the decline below the $95.10 close of 1 October 2026 and the $87.98 close of 14 October 2026. Further target cuts from Buy-rated firms would show the price weakness is spreading into analyst views. An on-time submission announcement, or a reported takeover approach, would strengthen the case.

What it trades with

Abivax trades mainly on its own regulatory timetable and on sentiment toward single-asset immunology biotechs. The Euronext Paris listing opens before the US session, so European trading often sets the ADS opening price. Its moves around the 30 June 2026 maintenance data (up 34.2% in one session per Benzinga) and the July offering show that company events, not index moves, drive the shares.